Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
Aurinia Pharmaceuticals(AUPH) Seeking Alpha·2024-09-19 11:55
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) is a biopharmaceutical company focused on autoimmune diseases. Currently, AUPH’s hit product is LUPKYNIS, which is indicated for managing lupus nephritis [LN]. LN is a complication of systemic lupus erythematosus [SLE]. Thus, LUPKYNIS is an FDA-approved treatment for LN that offersMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in compu ...